Tg Therapeutics (TGTX) Liabilities and Shareholders Equity (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Liabilities and Shareholders Equity of $1.5 billion for Q1 2026, up 132.81% year-over-year from $656.7 million in Q1 2025, and up 43.79% quarter-over-quarter from $1.1 billion in Q4 2025.
Tg Therapeutics (TGTX) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Tg Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 132.81% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $4.3 billion (up 94.44% YoY), while the FY2025 annual figure was $1.1 billion, up 84.05% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $1.5 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $1.5 billion in Q1 2026, with the low at $193.6 million in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $373.3 million (2024), against an average of $527.0 million.
- The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity plunged 49.01% in 2022, then jumped 132.81% in 2026.
- Tg Therapeutics' Liabilities and Shareholders Equity stood at $193.6 million in 2022, then surged by 70.27% to $329.6 million in 2023, then surged by 75.28% to $577.7 million in 2024, then jumped by 84.05% to $1.1 billion in 2025, then soared by 43.79% to $1.5 billion in 2026.
- Business Quant data shows TGTX's Liabilities and Shareholders Equity at $1.5 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 1.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.64 Bn |
| Mar 31, 2026 | 1.53 Bn |
| Dec 31, 2025 | 1.06 Bn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 702.61 Mn |
| Mar 31, 2025 | 656.69 Mn |
| Dec 31, 2024 | 577.69 Mn |
| Sep 30, 2024 | 586.01 Mn |
| Jun 30, 2024 | 401.21 Mn |
| Mar 31, 2024 | 373.32 Mn |
| Dec 31, 2023 | 329.59 Mn |
| Sep 30, 2023 | 331.07 Mn |
| Jun 30, 2023 | 220.85 Mn |
| Mar 31, 2023 | 197.36 Mn |
| Dec 31, 2022 | 193.57 Mn |
| Sep 30, 2022 | 217.89 Mn |
| Jun 30, 2022 | 251.67 Mn |
| Mar 31, 2022 | 303.03 Mn |
| Dec 31, 2021 | 379.63 Mn |
| Sep 30, 2021 | 409.69 Mn |